MoFo News Item

Morrison & Foerster Advises on Series D Private Equity Round for Paradigm


London, 18 July 2006 - Lawyers from the London office of Morrison & Foerster advised a group of investors including Avlar BioVentures, Bio*One Capital, Merlin Biosciences and Lloyds TSB Development Capital on a Series D private equity funding for Paradigm Therapeutics Limited ("Paradigm") totalling approximately £7 million.

Paradigm is a Cambridge-based drug discovery company.

The Morrison & Foerster team included Paul Claydon and James Halstead.




Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.